Latest Insider Transactions at Outset Medical, Inc. (OM)
This section provides a real-time view of insider transactions for Outset Medical, Inc. (OM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Outset Medical, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Outset Medical, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Leslie Trigg Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
625,000
+50.0%
|
-
|
|
Mar 10
2025
|
Karen Drexler Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
31,250
+50.0%
|
-
|
|
Mar 10
2025
|
Brent D. Lang Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
250,000
+50.0%
|
-
|
|
Mar 10
2025
|
D Keith Grossman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
187,500
+49.32%
|
-
|
|
Mar 10
2025
|
Patrick T Hackett Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,875,000
+50.0%
|
-
|
|
Mar 10
2025
|
Patrick T Hackett Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250,000
+49.16%
|
-
|
|
Feb 18
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
14,611
-1.63%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
6,145
-3.39%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
4,204
-2.05%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,659
-3.34%
|
$0
$0.9 P/Share
|
|
Jan 21
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
65,236
-2.3%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
34,288
-3.96%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
32,930
-5.21%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
23,221
-2.56%
|
$0
$0.8 P/Share
|
|
Jan 17
2025
|
Leslie Trigg Chair and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
99,419
+9.38%
|
-
|
|
Jan 17
2025
|
Nabeel Ahmed Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,256
+4.33%
|
-
|
|
Jan 17
2025
|
John L. Brottem General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+4.07%
|
-
|
|
Jan 17
2025
|
Marc Nash SVP Operations and R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,898
+1.28%
|
-
|
|
Jan 13
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
33,227
-3.71%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
15,011
-6.33%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,031
-9.4%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
20,492
-9.09%
|
$0
$0.81 P/Share
|
|
Jan 07
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
10,227
-1.13%
|
$10,227
$1.29 P/Share
|
|
Jan 07
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
1,572
-0.69%
|
$1,572
$1.29 P/Share
|
|
Jan 07
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
720
-0.3%
|
$720
$1.29 P/Share
|
|
Jan 07
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,835
-0.59%
|
$1,835
$1.29 P/Share
|
|
Nov 15
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
3,203
-1.39%
|
$0
$0.8 P/Share
|
|
Nov 15
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
1,375
-0.57%
|
$0
$0.8 P/Share
|
|
Nov 15
2024
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
5,645
-0.62%
|
$0
$0.8 P/Share
|
|
Nov 15
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,221
-1.34%
|
$0
$0.8 P/Share
|
|
Aug 15
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
1,293
-0.54%
|
$0
$0.84 P/Share
|
|
Aug 15
2024
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
5,308
-0.58%
|
$0
$0.84 P/Share
|
|
Aug 15
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,971
-1.25%
|
$0
$0.84 P/Share
|
|
Aug 15
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
3,011
-1.29%
|
$0
$0.84 P/Share
|
|
Jul 24
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
723
-0.3%
|
$2,892
$4.02 P/Share
|
|
Jun 12
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
10,569
-4.33%
|
$42,276
$4.78 P/Share
|
|
Jun 03
2024
|
D Keith Grossman Director |
SELL
Open market or private sale
|
Direct |
38,117
-24.63%
|
$114,351
$3.77 P/Share
|
|
Jun 03
2024
|
D Keith Grossman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,303
+30.18%
|
$69,303
$1.11 P/Share
|
|
May 29
2024
|
Dale E Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+35.25%
|
-
|
|
May 29
2024
|
Brent D. Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+15.82%
|
-
|
|
May 29
2024
|
Andrea Lynn Saia Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.3%
|
-
|
|
May 29
2024
|
Patrick T Hackett Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+36.85%
|
-
|
|
May 29
2024
|
James F. Hinrichs Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+23.73%
|
-
|
|
May 29
2024
|
Karen Drexler Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.14%
|
-
|
|
May 29
2024
|
D Keith Grossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+36.85%
|
-
|
|
May 16
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,918
-1.21%
|
$11,754
$3.53 P/Share
|
|
May 16
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
2,972
-1.2%
|
$8,916
$3.53 P/Share
|
|
May 16
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
1,097
-0.45%
|
$3,291
$3.53 P/Share
|
|
May 16
2024
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
5,237
-0.57%
|
$15,711
$3.53 P/Share
|
|
May 10
2024
|
Jean Olivier Racine Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,306
-3.04%
|
$24,918
$3.27 P/Share
|